No products in the cart.
![The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
5-day versus 10-day course of remdesivir in patients with severe COVID-19 [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Tag: remdesivir
The ACTT-1: Remdesivir for the treatment of COVID-19 [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
Remdesivir does not reduce mortality in ventilated patients with COVID-19
1. No significant decrease in mortality risk was seen in ventilated patients with COVID-19 on remdesivir compared to control. 2. ...
Molnupiravir does not improve clinical outcomes in patients hospitalized with COVID-19
1. Patients hospitalized with COVID-19 receiving at least one dose of molnupiravir did not show reduced mortality compared to patients ...
#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19
1. The use of COVID-19 convalescent plasma did not benefit patients hospitalized with COVID-19, assessed using the World Health Organization ...
5-day versus 10-day course of remdesivir in patients with severe COVID-19
1. Compared to patients who received remdesivir for 10 days, those in the 5-day group experienced no significant difference in ...
Remdesivir in adults with severe COVID-19
1. Adults with severe COVID-19 treated with remdesivir had numerically faster time to clinical improvement compared to controls, but the ...
#VisualAbstract: Compassionate Use of Remdesivir for Patients with Severe COVID-19
1. In this study, nearly 70% of patients who received remdesivir for compassionate use had an improvement in oxygen-support class ...
2 Minute Medicine Rewind May 4, 2020
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial 1. Adults with severe COVID-19 treated with remdesivir ...
Results from remdesivir compassionate use study for severe COVID-19
1. In this study, nearly 70% of patients who received remdesivir for compassionate use had an improvement in oxygen-support class ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.